LY311727

LY311727 Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  Secreted phospholipase A₂ (sPLA₂) isoforms are low molecular weight, millimolar calcium-dependent enzymes that hydrolyze the fatty acid from the sn-2 position of membrane phospholipids. Group IIA sPLA₂, also known as sPLA₂IIA and non-pancreatic sPLA₂, has roles in the regulation of eicosanoid synthesis and may modulate inflammatory signaling. LY311727 is an inhibitor of Group IIA sPLA₂ (IC₅₀ = 0.47 μM) that interacts with the active site of the enzyme in a non-covalent manner. It shows greater than 1,500-fold selectivity over pancreatic sPLA₂ (Group IB sPLA₂). LY311727 is commonly used to distinguish the actions of Group IIA sPLA₂ from those of other sPLA₂ isoforms in biological systems.

• Verwenden

  LY311727 is an inhibitor of Group IIA sPLA2 (IC50 = 0.47 μM) that interacts with the active site of the enzyme in a non-covalent manner. It shows greater than 1,500-fold selectivity over pancreatic sPLA2 (Group IB sPLA2). LY311727 is commonly used to distinguish the actions of Group IIA sPLA2 from those of other sPLA2 isoforms in biological systems.[Cayman Chemical]

• Verwenden

  LY 311727 is an inhibitor of secretory phospholipase A2 (sPLA2) and can be used to block Pseudomonas aeruginosa cytotoxicity. It can also attenuate VEGF-mediated platelet-activating factor (PAF) synthesis in HUVEC and BAEC cells.

• Biochem/physiol Actions

  LY311727 is an orally active; potent secretory Phospholipase A2 (sPLA2; Group IIa) inhibitor.

LY311727 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(43)Suppliers

164083-84-5, LY311727 Verwandte Suche: